419571-73-6 Usage
Uses
Used in Pharmaceutical Research and Development:
Tert-butyl 4-propionylpiperidine-1-carboxylate is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable building block in the creation of new medications, potentially leading to the development of innovative treatments for a range of health conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Tert-butyl 4-propionylpiperidine-1-carboxylate is employed as a key component in the design and synthesis of novel drug candidates. Its structural features enable chemists to explore its potential interactions with biological targets, which may contribute to the discovery of new therapeutic agents.
Used in Biological Activity Studies:
Tert-butyl 4-propionylpiperidine-1-carboxylate is used as a subject of investigation in biological activity studies. Researchers are interested in understanding its potential effects on biological systems, which could reveal its applicability in the treatment of specific health conditions or diseases.
Used in Chemical Synthesis Education:
In educational settings, particularly in chemistry and pharmaceutical courses, Tert-butyl 4-propionylpiperidine-1-carboxylate may be used as a teaching aid to demonstrate the synthesis of complex organic compounds and to familiarize students with the principles of medicinal chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 419571-73-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,9,5,7 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 419571-73:
(8*4)+(7*1)+(6*9)+(5*5)+(4*7)+(3*1)+(2*7)+(1*3)=166
166 % 10 = 6
So 419571-73-6 is a valid CAS Registry Number.
419571-73-6Relevant academic research and scientific papers
ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
-
Page/Page column 60, (2017/01/23)
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
-
Page/Page column 62, (2016/05/19)
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homo log 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
ANTIMALARIAL COMPOUNDS
-
Page/Page column 62; 68, (2012/06/15)
The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent ant
TASK CHANNEL ANTAGONISTS
-
Page/Page column 50, (2011/09/21)
This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders
TASK CHANNEL ANTAGONISTS
-
Page/Page column 50, (2011/09/30)
This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders
